<DOC>
	<DOCNO>NCT02079532</DOCNO>
	<brief_summary>This study evaluate efficacy safety MabThera patient active rheumatoid arthritis inadequate response one prior anti-TNF alpha inhibitor . MabThera-naive patient stratify 3 arm , accord previous inadequate response ) etanercept , b ) infliximab c ) adalimumab . Patients treat MabThera ( 1g infusion ) day 1 day 15 , continue basic methotrexate therapy . The anticipated time study treatment 2+ year , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Patients With Rheumatoid Arthritis Who Have Had Inadequate Response Single Anti-TNF Inhibitor</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patient , 1875 year age ; rheumatoid arthritis &gt; =6 month ; previous inadequate response single antiTNF alpha inhibitor ; methotrexate stable dose range 7.525 mg/week . chronic inflammatory articular disease systemic autoimmune disease ; previous treatment MabThera intolerance MabThera ; corticosteroid &gt; =10 mg/day prednisolone within last 2 week , corticosteroid unstable dos within last 2 week ;</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>